Polish Stem Cells Bank (PBKM)/ FamiCord Group

famicord.eu

The Polish Stem Cells Bank (PBKM) is operating on the international market under the brand of FamiCord Group, which was founded in 2002. It is a stem cell bank, engaged in the acquisition, processing and long-term storage of stem cells taken from umbilical cord blood and other fetal tissues on behalf of parents – family banking. The aim of PBKM is to ensure access of the family for stem cells in case of need for therapy. As of 2017 FamiCord has released more than 30 units of cord blood for transplantatation and more than 1000 units of stem cells from other sources. Currently Famicord Group operates directly in Poland, Spain, Turkey, Latvia, Hungary, Romania, Italy and through business partners in Sweden, Ukraine, Serbia and UK .

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

SPECTRUMX CONFIRMS NEXT STEP IN CLINICAL DEVELOPMENT OF RESPIRATORY DRUG CANDIDATE SPX-001 AFTER MHRA MEETING

SpectrumX | November 25, 2022

news image

SpectrumX, a UK-based healthcare and pharmaceutical company announces that following a constructive scientific advice meeting with the Medicines and Healthcare products Regulatory Agency on Monday, 14th November, the Company is prepared to move forward with the next stage in clinical development of its respiratory drug candidate SPX-001. Per regulatory guidelines, SpectrumX will submit a combined Clinical Trial and Ethics Committee application for a placebo-controlled phase Ib inf...

Read More

MedTech

OUTCOMES4ME PARTNERS WITH INVITAE TO OFFER GENETIC TESTING TO BREAST CANCER PATIENTS

Outcomes4Me | October 12, 2021

news image

Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, today announced that it has partnered with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to expand education and access to genetic testing to breast cancer patients and survivors. The collaboration leverages the strengths of Invitae, which supplies clinical grade genetic testing, and Outcomes4Me’s 360-degree, validated and evidence-based cancer support and tr...

Read More

Research

ABVERIS ANNOUNCES MULTI-TARGET, MULTI-YEAR THERAPEUTIC ANTIBODY DISCOVERY COLLABORATION WITH PROMETHEUS BIOSCIENCES

Abveris, Biosciences | November 12, 2021

news image

Abveris, a leader in antibody drug discovery announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets. The partnership will expand Abveris's role in supporting the rapid development of the Prometheus Biosciences portfolio. The results of the collaboration will bring promising new therapeutics to patients suffering from a variety of immune-mediated diseases. Under this partnership agreem...

Read More

MedTech, Medical

PATENT AWARDED FOR PRIMARY TEMPLATE-DIRECTED AMPLIFICATION, FURTHER STRENGTHENING BIOSKRYB GENOMICS’ CORE TECHNOLOGIES

Businesswire | August 21, 2023

news image

BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, today announced the issuance of a composition of matter patent, US Patent 11,643,682 by the U.S. Patent and Trademark Office related to its novel Primary Template-Directed Amplification (PTA) method and applications for research, diagnostics, and treatment. The patent is exclusively licensed to BioSkryb by St. Jude Children&rs...

Read More
news image

MedTech

SPECTRUMX CONFIRMS NEXT STEP IN CLINICAL DEVELOPMENT OF RESPIRATORY DRUG CANDIDATE SPX-001 AFTER MHRA MEETING

SpectrumX | November 25, 2022

SpectrumX, a UK-based healthcare and pharmaceutical company announces that following a constructive scientific advice meeting with the Medicines and Healthcare products Regulatory Agency on Monday, 14th November, the Company is prepared to move forward with the next stage in clinical development of its respiratory drug candidate SPX-001. Per regulatory guidelines, SpectrumX will submit a combined Clinical Trial and Ethics Committee application for a placebo-controlled phase Ib inf...

Read More
news image

MedTech

OUTCOMES4ME PARTNERS WITH INVITAE TO OFFER GENETIC TESTING TO BREAST CANCER PATIENTS

Outcomes4Me | October 12, 2021

Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, today announced that it has partnered with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to expand education and access to genetic testing to breast cancer patients and survivors. The collaboration leverages the strengths of Invitae, which supplies clinical grade genetic testing, and Outcomes4Me’s 360-degree, validated and evidence-based cancer support and tr...

Read More
news image

Research

ABVERIS ANNOUNCES MULTI-TARGET, MULTI-YEAR THERAPEUTIC ANTIBODY DISCOVERY COLLABORATION WITH PROMETHEUS BIOSCIENCES

Abveris, Biosciences | November 12, 2021

Abveris, a leader in antibody drug discovery announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets. The partnership will expand Abveris's role in supporting the rapid development of the Prometheus Biosciences portfolio. The results of the collaboration will bring promising new therapeutics to patients suffering from a variety of immune-mediated diseases. Under this partnership agreem...

Read More
news image

MedTech, Medical

PATENT AWARDED FOR PRIMARY TEMPLATE-DIRECTED AMPLIFICATION, FURTHER STRENGTHENING BIOSKRYB GENOMICS’ CORE TECHNOLOGIES

Businesswire | August 21, 2023

BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, today announced the issuance of a composition of matter patent, US Patent 11,643,682 by the U.S. Patent and Trademark Office related to its novel Primary Template-Directed Amplification (PTA) method and applications for research, diagnostics, and treatment. The patent is exclusively licensed to BioSkryb by St. Jude Children&rs...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us